Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia

Future Neurology “Real-world insights into idiopathic hypersomnia symptoms, treatments, and quality of life from the ARISE study: a Plain Language Summary of Publication”

The Power of Being Seen: Narcolepsy and Mental Health

High Blood Pressure Doesn’t Sleep — What You Should Know

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

ONSTRIDE-1: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants with Narcolepsy Followed by an Open-label Extension

Illuminate Brain Fog

Wake Up Narcolepsy 2026 National Summit Recap

Institute for Clinical and Economic Review Releases Evidence Report on Treatment for Narcolepsy

Now enrolling: Brilliance clinical studies for narcolepsy type 1